323 related articles for article (PubMed ID: 35790906)
1. Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings.
Polavieja P; Belger M; Venkata SK; Wilhelm S; Johansson E
J Headache Pain; 2022 Jul; 23(1):76. PubMed ID: 35790906
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis.
Johnston K; Popoff E; Deighton A; Dabirvaziri P; Harris L; Thiry A; Croop R; Coric V; L'Italien G; Moren J
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):155-166. PubMed ID: 34148501
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effectiveness and safety of lasmiditan and CGRP-antagonists for the acute treatment of migraine in adults: systematic review and network meta-analysis of randomised trials.
Deng X; Zhou L; Liang C; Shang X; Hui X; Liu W; Liang S; Wang Y; Xu M; Guo K; Yang K; Li X
J Headache Pain; 2024 Feb; 25(1):16. PubMed ID: 38311738
[TBL] [Abstract][Full Text] [Related]
4. Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm.
Johnston KM; Powell L; Popoff E; Harris L; Croop R; Coric V; L'Italien G
Clin J Pain; 2022 Nov; 38(11):680-685. PubMed ID: 36125279
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.
Joyner KR; Morgan KW
Ann Pharmacother; 2021 Jun; 55(6):745-759. PubMed ID: 32993366
[TBL] [Abstract][Full Text] [Related]
6. Comparison of New Pharmacologic Agents With Triptans for Treatment of Migraine: A Systematic Review and Meta-analysis.
Yang CP; Liang CS; Chang CM; Yang CC; Shih PH; Yau YC; Tang KT; Wang SJ
JAMA Netw Open; 2021 Oct; 4(10):e2128544. PubMed ID: 34633423
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, safety and indirect comparisons of lasmiditan, rimegepant, and ubrogepant for the acute treatment of migraine: A systematic review and network meta-analysis of the literature.
Puledda F; Younis S; Huessler EM; Haghdoost F; Lisicki M; Goadsby PJ; Tassorelli C
Cephalalgia; 2023 Mar; 43(3):3331024231151419. PubMed ID: 36786357
[TBL] [Abstract][Full Text] [Related]
8. Short-term efficacy and safety of lasmiditan, a novel 5-HT
Hou M; Xing H; Li C; Wang X; Deng D; Li J; Zhang P; Chen J
J Headache Pain; 2020 Jun; 21(1):66. PubMed ID: 32503415
[TBL] [Abstract][Full Text] [Related]
9. Budget impact of lasmiditan for the acute treatment of migraine in the United States.
Milev S; Pohl G; Sun A; Mason O; Njuguna N; Loo LS
J Manag Care Spec Pharm; 2021 Dec; 27(12):1714-1723. PubMed ID: 34818093
[No Abstract] [Full Text] [Related]
10. The Effect and Safety of 5-HT
Gu P; Chen C; Wu Q; Dong C; Wang T; Wan Q; Dong X
Biomed Res Int; 2021; 2021():6663591. PubMed ID: 34660796
[TBL] [Abstract][Full Text] [Related]
11. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
12. Ubrogepant for the Treatment of Migraine.
Dodick DW; Lipton RB; Ailani J; Lu K; Finnegan M; Trugman JM; Szegedi A
N Engl J Med; 2019 Dec; 381(23):2230-2241. PubMed ID: 31800988
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
[TBL] [Abstract][Full Text] [Related]
14. Lasmiditan in patients with common migraine comorbidities: a
Clemow DB; Baygani SK; Hauck PM; Hultman CB
Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
[TBL] [Abstract][Full Text] [Related]
15. Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Yang Y; Sun Y; Gao B; Wang Z; Chen Z; Wang Z
CNS Drugs; 2020 Oct; 34(10):1015-1024. PubMed ID: 32857291
[TBL] [Abstract][Full Text] [Related]
16. Ditans vs Gepants: A Systematic Review and Indirect Network Meta-Analysis for Comparative Analysis of Efficacy and Safety.
Singh A; Gupta D; Singh A
Neurol India; 2021; 69(Supplement):S43-S50. PubMed ID: 34003147
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
[TBL] [Abstract][Full Text] [Related]
18. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
19. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
20. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
